drugset / Trial / NCT05541549
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blinded, Phase 2 trial in patients with PML due to JCPyV. Patients will receive treatment with a matched virus-specific T-cell product (CE VST01-JC) or placebo, and will then be monitored for response to therapy.
Timeline
- Start
- 2023-02
- Primary completion
- 2024-03
- Completion
- 2025-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CE-VST01-JC | Cell therapy | 1e+08 cells | Intravenous |